Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Early Return of Raised Funds Used to Temporarily Supplement Working Capital

Sep 24, 2026 · Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Sep 24, 2026

Announcement on Early Return of Raised Funds Used to Temporarily Supplement Working Capital

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Triggering of Milestone Payment Conditions under the Global Strategic Collaboration Agreement between Its Wholly-owned Subsidiary SystImmune and Bristol Myers Squibb for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren)Sep 22
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Joint Investment with Related PartiesSep 18
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for Neoadjuvant Therapy in HER2-positive Breast CancerSep 14
"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) for Maintenance Therapy After Concurrent Chemoradiotherapy in Unresectable EGFR-Mutant Non-Small Cell Lung CancerSep 10

All Sichuan Biokin Pharmaceutical Co., Ltd. Class A news releases